SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Young NS. Acquired aplastic anemia. In: YoungNS, editor. The bone marrow failure syndromes. Philadelphia: W.B. Saunders; 2000. p 146.
  • 2
    Young NS. Agranulocytosis. In: YoungNS, editor. The bone marrow failure syndromes. Philadelphia: W.B. Saunders; 2000. p 156182.
  • 3
    Kaufman DW, Kelly JP, Levy M, Shapiro S. The drug etiology of agranulocytosis and aplastic anemia: the International Agranulocytosis and Aplastic Anemia Study. New York: Oxford University Press; 1991.
  • 4
    Kaufman DW, Kelly JP, Jurgelon J, et al. Drugs in the etiology of agranulocytosis and aplastic anemia. Eur J Haematol 1996; 57(Suppl):2330.
  • 5
    Issaragrisil S, Kaufman DW, Anderson T, et al. Low drug attributability of aplastic anemia in Thailand. Blood 1997;89:40344039.
  • 6
    Shapiro S, Issaragrisil S, Kaufman DW, et al. Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Am J Trop Med Hyg 1999;60:573577.
  • 7
    Peng J, Liu C, Zhu K, et al. The TNF2 allele is a risk factor to severe aplastic anemia independent of HLA-DR. Hum Immunol 2003;64:896901.
  • 8
    Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 1994;84:42574261.
  • 9
    Fogarty PF, Yamaguchi H, Wiestner A, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in the telomerase RNA. Lancet 2003;362:16281630.